entrar registro
function
#6 function
 *
#5 Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: pubmed.ncbi.nlm.nih.gov/34462647/

Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34325334/

Tolosa-Hunt syndrome occurring after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34513398/

Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34362727/

Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): pubmed.ncbi.nlm.nih.gov/34469919/.

Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: pubmed.ncbi.nlm.nih.gov/34516272/.

Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: pubmed.ncbi.nlm.nih.gov/34512961/

Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34077949/

Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): pubmed.ncbi.nlm.nih.gov/34171435/

Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34447349/

Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34514078/

Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34406660/.

IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34509658/

A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34196469/.

Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca / Covishield): report of two cases: pubmed.ncbi.nlm.nih.gov/34350668/

Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34436620/

Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: pubmed.ncbi.nlm.nih.gov/34116295/.

COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern in cases with underlying hepatic problems: pubmed.ncbi.nlm.nih.gov/34509271/.

Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34462996/

Immune thrombocytopenia after vaccination during the COVID-19 pandemic: pubmed.ncbi.nlm.nih.gov/34435486/

COVID-19: lessons from the Norwegian tragedy should be taken into account in planning for vaccine launch in less developed/developing countries: pubmed.ncbi.nlm.nih.gov/34435142/

Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34429981/

Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: pubmed.ncbi.nlm.nih.gov/34427024/

Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34510014/.

Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34236711/

Vaccine-induced thrombocytopenia with severe headache: pubmed.ncbi.nlm.nih.gov/34525282/

Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34515024/

Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34435250/.

Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: pubmed.ncbi.nlm.nih.gov/34363637/

Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2: www.sciencedirect.com/science/article/pii/S2214250921002018

Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination: casereports.bmj.com/content/14/5/e242220.abstract.

Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34155844/

Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration: www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/.

Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine: www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext.

Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2: www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/.

Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination: casereports.bmj.com/content/14/7/e242678.

Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination: ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-

Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria: ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines

Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: pubmed.ncbi.nlm.nih.gov/34288044/.

Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: pubmed.ncbi.nlm.nih.gov/34327553/.

Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33878469/.

Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: pubmed.ncbi.nlm.nih.gov/33857630/.

Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34090750/.

Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34312301/.

Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34333995/

The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34455073/

Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34111775/.

Cerebral venous thrombosis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34045111/

Lethal cerebral venous sinus thrombosis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33983464/

Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: pubmed.ncbi.nlm.nih.gov/34116145/

Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular administration of the vaccine: pubmed.ncbi.nlm.nih.gov/34286453/.

Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19 mRNA vaccination: are these reports merely coincidental: pubmed.ncbi.nlm.nih.gov/34478433/

Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: pubmed.ncbi.nlm.nih.gov/34244448/

Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34226070/

Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19: pubmed.ncbi.nlm.nih.gov/33845870/.

Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34101024/.

Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with a high mortality rate: a case series: pubmed.ncbi.nlm.nih.gov/34393988/.

Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: pubmed.ncbi.nlm.nih.gov/34407607/.

Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study: pubmed.ncbi.nlm.nih.gov/34313952/

Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST): pubmed.ncbi.nlm.nih.gov/34092166/

Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an analysis of cases reported to the European Medicines Agency: pubmed.ncbi.nlm.nih.gov/34293217/

A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: pubmed.ncbi.nlm.nih.gov/34274191/

Cerebral venous sinus thrombosis negative for anti-PF4 antibody without thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid elderly Indian male treated with conventional heparin-warfarin-based anticoagulation: pubmed.ncbi.nlm.nih.gov/34186376/

Arterial events, venous thromboembolism, thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population-based cohort study: pubmed.ncbi.nlm.nih.gov/33952445/

Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis: pubmed.ncbi.nlm.nih.gov/34129181/

U.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination...
0    k 20
function
#7 function
 *
#6 U.S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after vaccination with Ad26.COV2.S, March 2-April 21, 2021: pubmed.ncbi.nlm.nih.gov/33929487/.

Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a catastrophic variant of vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34341358/

Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: pubmed.ncbi.nlm.nih.gov/34175640/

Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: pubmed.ncbi.nlm.nih.gov/34159588/.

Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/

Autoimmunity roots of thrombotic events after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34508917/

Cerebral venous sinus thrombosis after vaccination: the UK experience: pubmed.ncbi.nlm.nih.gov/34370974/

Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: pubmed.ncbi.nlm.nih.gov/34373991/

Australian and New Zealand approach to the diagnosis and treatment of vaccine-induced immune thrombosis and immune thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34490632/

An observational study to identify the prevalence of thrombocytopenia and anti-PF4 / polyanion antibodies in Norwegian health care workers after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33909350/

Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: pubmed.ncbi.nlm.nih.gov/33981305/.

A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. pubmed.ncbi.nlm.nih.gov/34272622/

Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine:. pubmed.ncbi.nlm.nih.gov/33877737/

Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34254476/

First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: pubmed.ncbi.nlm.nih.gov/34108714/

ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand: pubmed.ncbi.nlm.nih.gov/34483267/.

Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34261635/

Neurosurgical considerations with respect to decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic thrombocytopenia-VITT: pubmed.ncbi.nlm.nih.gov/34202817/

Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report: pubmed.ncbi.nlm.nih.gov/34273119/

Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: pubmed.ncbi.nlm.nih.gov/34463066/

A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34276917/

Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34237213/.

Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34268278/.

Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/33990339/.

Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: pubmed.ncbi.nlm.nih.gov/34479760/.

Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: pubmed.ncbi.nlm.nih.gov/34314875/.

Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34384129/

Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after successful initial therapy with intravenous immunoglobulins: a rationale for monitoring immunoglobulin G levels: pubmed.ncbi.nlm.nih.gov/34382387/

A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: pubmed.ncbi.nlm.nih.gov/34416184/.

Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: pubmed.ncbi.nlm.nih.gov/34261297/

Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34261296/

Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: pubmed.ncbi.nlm.nih.gov/34250318/.

A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis: pubmed.ncbi.nlm.nih.gov/34059191/

Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34189756/

Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34331506/

Vaccine-induced thrombocytopenia with severe headache: pubmed.ncbi.nlm.nih.gov/34525282/

Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: www.medrxiv.org/content/10.1101/2021.08.30.21262866v1

COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis: www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09.

Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine: onlinelibrary.wiley.com/doi/10.1111/trf.16672

Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: t.co/j0IEM8cMXI

A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System. (VAERS) in association with COVID-19 injectable biologics: pubmed.ncbi.nlm.nih.gov/34601006/

This study concludes that: “The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection”: www.nejm.org/doi/full/10.1056/NEJMoa2110475

Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: www.sciencedirect.com/science/article/pii/S1201971221007797

Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database: www.medrxiv.org/content/10.1101/2021.08.30.21262866v1.

Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: www.sciencedirect.com/science/article/pii/S0168827821020936

Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: www.nature.com/articles/s41421-021-00329-3

Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/

Mrna COVID vaccines dramatically increase endothelial inflammatory markers and risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution: www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome:www.science.org/doi/10.1126/sciadv.abl8213

Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT) following announcement 26.COV2.S: first documented case outside the U.S.: pubmed.ncbi.nlm.nih.gov/34626338/

A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: europepmc.org/article/PPR/PPR304469 435.

VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34731555/

Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new clinicopathologic entity with heterogeneous clinical presentations: pubmed.ncbi.nlm.nih.gov/34159588/

Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34461442/

Spectrum of neurological complications after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34719776/.

Cerebral venous sinus thrombosis after vaccination: the UK experience: pubmed.ncbi.nlm.nih.gov/34370974/

Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34373413/

Portal vein thrombosis due to vaccine-induced immune thrombotic immune thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34598301/

Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca...
0    k 17
function
#8 function
 *
#7 Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34620638/

Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: pubmed.ncbi.nlm.nih.gov/34650896/

Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34625447/

Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with teriflunomide: pubmed.ncbi.nlm.nih.gov/34696248/

Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34548920/

Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): pubmed.ncbi.nlm.nih.gov/34672380/.

Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: pubmed.ncbi.nlm.nih.gov/34556531/.

Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: pubmed.ncbi.nlm.nih.gov/34535076/.

Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: pubmed.ncbi.nlm.nih.gov/34379914/.

Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: pubmed.ncbi.nlm.nih.gov/34545400/

Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34035134/

In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34688190/

Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three cases: pubmed.ncbi.nlm.nih.gov/34782400/

Cardiovascular, neurological, and pulmonary events after vaccination with BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data: pubmed.ncbi.nlm.nih.gov/34710832/

Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: pubmed.ncbi.nlm.nih.gov/34695859/

Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: pubmed.ncbi.nlm.nih.gov/34453762/.

Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: pubmed.ncbi.nlm.nih.gov/34660652/.

Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical thrombectomy: pubmed.ncbi.nlm.nih.gov/34644642/

Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: pubmed.ncbi.nlm.nih.gov/34694650/

Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34726934/

Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: pubmed.ncbi.nlm.nih.gov/34835237/

Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: pubmed.ncbi.nlm.nih.gov/34261297/

Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34724036/.

Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34839563/

Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34783932/.

COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: pubmed.ncbi.nlm.nih.gov/34624910/

Inflammatory myositis after vaccination with ChAdOx1: pubmed.ncbi.nlm.nih.gov/34585145/

Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34580132/.

A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) affecting the venosplanchnic and pulmonary arterial circulation from a UK district general hospital: pubmed.ncbi.nlm.nih.gov/34535492/

COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series: pubmed.ncbi.nlm.nih.gov/34527501/

Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons <60% risk-benefit analysis for people <60 years in Australia: pubmed.ncbi.nlm.nih.gov/34272095/

Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: pubmed.ncbi.nlm.nih.gov/34756770/

Characteristics and outcomes of patients with cerebral venous sinus thrombosis in thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: jamanetwork.com/journals/jamaneurology/fullarticle/2784622

Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34781321/

Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines: pubmed.ncbi.nlm.nih.gov/34062319/

Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case of definite thrombosis with thrombocytopenia syndrome in India: pubmed.ncbi.nlm.nih.gov/34706921/

COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: pubmed.ncbi.nlm.nih.gov/34698582/.

Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34751013/.

Acute transverse myelitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34684047/.

Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34541935/

Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report: pubmed.ncbi.nlm.nih.gov/34273119/

Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: pubmed.ncbi.nlm.nih.gov/34327553/.

Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently vaccinated with an adenoviral vector-based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33877737/

Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34646685/

Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34242687/.

Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34609603/

Case report: Pityriasis rosea-like rash after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34557507/

Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34641797/.

Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222: pubmed.ncbi.nlm.nih.gov/34812326/.

Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19 mRNA vaccines reported to the Vaccine Adverse Event Reporting System (VAERS): pubmed.ncbi.nlm.nih.gov/34006408/

A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: pubmed.ncbi.nlm.nih.gov/34416184/

Vaccine-induced immune thrombosis and thrombocytopenia syndrome after adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a new hypothesis on mechanisms and implications for future vaccine development: pubmed.ncbi.nlm.nih.gov/34664303/.

Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34649281/.

Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: pubmed.ncbi.nlm.nih.gov/34420249/

Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: systematic review and meta-analysis: pubmed.ncbi.nlm.nih.gov/34610990/.

Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman: pubmed.ncbi.nlm.nih.gov/34590397/

Sudden sensorineural hearing loss after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34670143/.

Prevalence of serious adverse events among health care professionals after receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021: pubmed.ncbi.nlm.nih.gov/34819146/.

Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination: pubmed.ncbi.nlm.nih.gov/34581453/

Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy: pubmed.ncbi.nlm.nih.gov/34741583/

Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report: pubmed.ncbi.nlm.nih.gov/34631069/

Thrombosis after COVID-19 vaccination: possible link to ACE pathways: pubmed.ncbi.nlm.nih.gov/34479129/

Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34331506/

Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant): pubmed.ncbi.nlm.nih.gov/34546608/

Abdominal pain and bilateral...
0    k 17
function
#9 function
 *
#8 Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced by COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34546343/

Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34849183/

Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34853744/.

A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): pubmed.ncbi.nlm.nih.gov/34751429/.

Ocular adverse events following COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34559576/

Depression after ChAdOx1-S / nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34608345/.

Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34384129/.

Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: pubmed.ncbi.nlm.nih.gov/34755433/

Major artery thrombosis and vaccination against ChAdOx1 nCov-19: pubmed.ncbi.nlm.nih.gov/34839830/

Rare case of contralateral supraclavicular lymphadenopathy after vaccination with COVID-19: computed tomography and ultrasound findings: pubmed.ncbi.nlm.nih.gov/34667486/

Cutaneous lymphocytic vasculitis after administration of the second dose of AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2 vaccine: chance or causality: pubmed.ncbi.nlm.nih.gov/34726187/.

Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: pubmed.ncbi.nlm.nih.gov/34781027/

Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: pubmed.ncbi.nlm.nih.gov/34595694/

Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers: pubmed.ncbi.nlm.nih.gov/34661934/

Comments on thrombosis after vaccination: spike protein leader sequence could be responsible for thrombosis and antibody-mediated thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34788138

Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34753210/.

Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: pubmed.ncbi.nlm.nih.gov/34653943/.

Relapse of immune thrombocytopenia after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34591991/

Thrombosis in pre- and post-vaccination phase of COVID-19; pubmed.ncbi.nlm.nih.gov/34650382/

A look at the role of postmortem immunohistochemistry in understanding the inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic adverse events: a narrative review: pubmed.ncbi.nlm.nih.gov/34769454/

COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective: pubmed.ncbi.nlm.nih.gov/34786893/

Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: pubmed.ncbi.nlm.nih.gov/34833382/

Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): pubmed.ncbi.nlm.nih.gov/34670287/

An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34790811/

Immediate high-dose intravenous immunoglobulins followed by direct treatment with thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of the cerebral sinus and portal vein: pubmed.ncbi.nlm.nih.gov/34023956/.

Thrombosis formation after COVID-19 vaccination immunologic aspects: review article: pubmed.ncbi.nlm.nih.gov/34629931/

Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): pubmed.ncbi.nlm.nih.gov/34402666/

Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: pubmed.ncbi.nlm.nih.gov/34842783/

Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after COVID-19 vaccination in a Taiwanese man: a case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34630307/

Fatal cerebral venous sinus thrombosis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33983464/

Autoimmune roots of thrombotic events after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34508917/.

New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext.

Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca {0xae} COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33962903/.

Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: pubmed.ncbi.nlm.nih.gov/34796065/.

Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: pubmed.ncbi.nlm.nih.gov/34579248/

A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis: pubmed.ncbi.nlm.nih.gov/34843991/

Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): pubmed.ncbi.nlm.nih.gov/34595867/

A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech): pubmed.ncbi.nlm.nih.gov/34820240/

Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting pathologic mechanisms with Bruton’s tyrosine kinase inhibitors: pubmed.ncbi.nlm.nih.gov/33851389/

Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S: pubmed.ncbi.nlm.nih.gov/33980419/

Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34264151/

Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen: pubmed.ncbi.nlm.nih.gov/34734086/

Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: pubmed.ncbi.nlm.nih.gov/34755555/

Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34407607/

Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine: pubmed.ncbi.nlm.nih.gov/34264514/.

Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19): pubmed.ncbi.nlm.nih.gov/34840204/

Neurological side effects of SARS-CoV-2 vaccines: pubmed.ncbi.nlm.nih.gov/34750810/

Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways: pubmed.ncbi.nlm.nih.gov/34639132/

Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up: pubmed.ncbi.nlm.nih.gov/34804412/

Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report: pubmed.ncbi.nlm.nih.gov/34571653/.

Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: pubmed.ncbi.nlm.nih.gov/34835275/.

Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males: pubmed.ncbi.nlm.nih.gov/34659839/.

Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34668274/.

Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34549821/

Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant): pubmed.ncbi.nlm.nih.gov/34528522/

Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/

Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/.

Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate: academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408

Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: www.mdpi.com/2075-4426/11/11/1106

Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/

Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/

Myocarditis Following mRNA COVID-19 Vaccine: journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx.

Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel: pubmed.ncbi.nlm.nih.gov/34614328/.

Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination: www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext

Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34277198/

Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: pubmed.ncbi.nlm.nih.gov/34246586/

Hypersensitivity Myocarditis and...
0    k 17
function
#9 Hypersensitivity Myocarditis and COVID-19 Vaccines: pubmed.ncbi.nlm.nih.gov/34856634/.

Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7.

Acute myocardial infarction and myocarditis after COVID-19 vaccination: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/

Myocarditis after Covid-19 vaccination in a large healthcare organization: www.nejm.org/doi/10.1056/NEJMoa2110737

Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children: jamanetwork.com/journals/jamacardiology/fullarticle/2783052

Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=

STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. pubmed.ncbi.nlm.nih.gov/34756746/

Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/

Myocarditis after COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34546329/.

Patients with acute myocarditis after COVID-19 mRNA vaccination:. jamanetwork.com/journals/jamacardiology/fullarticle/2781602.

Myocarditis after COVID-19 vaccination: a case series: www.sciencedirect.com/science/article/pii/S0264410X21011725?via=ihub.

Myocarditis associated with COVID-19 vaccination in adolescents: publications.aap.org/pediatrics/article/148/5/e2021053427/181357

Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:. pubmed.ncbi.nlm.nih.gov/34704459/

Myocarditis after COVID-19 vaccination: magnetic resonance imaging study: academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230.

Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/

Myocarditis after COVID-19 vaccination: www.sciencedirect.com/science/article/pii/S2352906721001603

Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: pubmed.ncbi.nlm.nih.gov/34712717/.

Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administ.

Myocarditis associated with COVID-19 mRNA vaccination: pubs.rsna.org/doi/10.1148/radiol.2021211430

Acute myocarditis after COVID-19 vaccination: a case report: www.sciencedirect.com/science/article/pii/S0248866321007098

Acute myopericarditis after COVID-19 vaccination in adolescents:. pubmed.ncbi.nlm.nih.gov/34589238/.

Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination: academic.oup.com/jpids/article/10/10/962/6329543.

Acute myocarditis associated with anti-COVID-19 vaccination: ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196.

Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:. pubmed.ncbi.nlm.nih.gov/34428917/.

Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination:. pubmed.ncbi.nlm.nih.gov/34088762/.

Myocarditis and pericarditis in adolescents after first and second doses of COVID-19 mRNA vaccines:. academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/6.

COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis: www.mdpi.com/2036-7503/13/3/61.

Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: pubmed.ncbi.nlm.nih.gov/34402228/

Myocarditis temporally associated with COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34133885/

Acute myocardial injury after COVID-19 vaccination: a case report and review of current evidence from the vaccine adverse event reporting system database: pubmed.ncbi.nlm.nih.gov/34219532/

Acute myocarditis associated with COVID-19 vaccination: report of a case: www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/

Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series: pubmed.ncbi.nlm.nih.gov/34840235/.

Myocarditis in the setting of a recent COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34712497/.

Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases: www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext.

Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: pubmed.ncbi.nlm.nih.gov/34568726/

Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/

Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination: academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408.

Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: www.mdpi.com/2075-4426/11/11/1106

Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study: pubmed.ncbi.nlm.nih.gov/34402230/

Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: pubmed.ncbi.nlm.nih.gov/34696294/

Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34615534/

Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination: pubmed.ncbi.nlm.nih.gov/34352418/

Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19; jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340.

CAd26.COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous sinus thrombosis in a young man with normal platelet count: pubmed.ncbi.nlm.nih.gov/34632750/

Post-mortem findings in vaccine-induced thrombotic thrombocytopenia: haematologica.org/article/view/haematol.2021.279075

COVID-19 vaccine-induced thrombosis: pubmed.ncbi.nlm.nih.gov/34802488/.

Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis: pubmed.ncbi.nlm.nih.gov/34887867/.

Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34863404/.

Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford-AstraZeneca COVID-19: a missed opportunity for rapid return on experience: www.sciencedirect.com/science/article/pii/S235255682100093X

Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34876440/

Deep venous thrombosis more than two weeks after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/33928773/

Case report: Take a second look: Cerebral venous thrombosis related to Covid-19 vaccination and thrombotic thrombocytopenia syndrome: pubmed.ncbi.nlm.nih.gov/34880826/

Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia: pubmed.ncbi.nlm.nih.gov/34587242/

Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: pubmed.ncbi.nlm.nih.gov/34868465/

Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): pubmed.ncbi.nlm.nih.gov/34097311/

Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia or a coincidence due to underlying risk factors: pubmed.ncbi.nlm.nih.gov/34820232/.

Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt and thrombectomy: onlinelibrary.wiley.com/doi/10.1002/ajh.26258

Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: pubmed.ncbi.nlm.nih.gov/34579636/

Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient: pubmed.ncbi.nlm.nih.gov/34614491/

Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a patient with pancreatic cancer after vaccination with messenger RNA-1273: pubmed.ncbi.nlm.nih.gov/34790684/

Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19): pubmed.ncbi.nlm.nih.gov/33624509/.

Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): pubmed.ncbi.nlm.nih.gov/34612003/

Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: pubmed.ncbi.nlm.nih.gov/34096082/

Myocarditis associated with COVID-19 vaccination in three adolescent boys: pubmed.ncbi.nlm.nih.gov/34851078/.

Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series: pubmed.ncbi.nlm.nih.gov/34496880/

Perimyocarditis...
0    k 17
function
#10 Perimyocarditis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34866957/

Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: pubmed.ncbi.nlm.nih.gov/34849657/.

Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings: pubmed.ncbi.nlm.nih.gov/34664804/

Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: pubmed.ncbi.nlm.nih.gov/34605853/

Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: pubmed.ncbi.nlm.nih.gov/34166671/

Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34744118/

Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male: pubmed.ncbi.nlm.nih.gov/34334935/.

Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: pubmed.ncbi.nlm.nih.gov/34746968/

Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?”: pubmed.ncbi.nlm.nih.gov/34333695/.

Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine: pubmed.ncbi.nlm.nih.gov/34180390/

Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: pubmed.ncbi.nlm.nih.gov/34185045/

Myocarditis after BNT162b2 vaccination in a healthy male: pubmed.ncbi.nlm.nih.gov/34229940/

Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: pubmed.ncbi.nlm.nih.gov/34133825/

Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34308326/.

Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: pubmed.ncbi.nlm.nih.gov/34866106/

Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: pubmed.ncbi.nlm.nih.gov/34487236/

Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273: pubmed.ncbi.nlm.nih.gov/34848416/

Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: pubmed.ncbi.nlm.nih.gov/34636504/

Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34367386/

Acute myocarditis in a young adult two days after vaccination with Pfizer: pubmed.ncbi.nlm.nih.gov/34709227/

Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation: pubmed.ncbi.nlm.nih.gov/34778411/

Acute myocarditis after 2019 coronavirus disease vaccination: pubmed.ncbi.nlm.nih.gov/34734821/

A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: pubmed.ncbi.nlm.nih.gov/34246585/

Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents: pubmed.ncbi.nlm.nih.gov/34228985/

Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34852213/

Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease: pubmed.ncbi.nlm.nih.gov/34866122/

Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination: pubmed.ncbi.nlm.nih.gov/34601566/

Myocarditis following COVID-19 vaccination: MRI study: pubmed.ncbi.nlm.nih.gov/34739045/.

Acute myocarditis after COVID-19 vaccination: case report: docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e

Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children: pubmed.ncbi.nlm.nih.gov/34374740/

Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: pubmed.ncbi.nlm.nih.gov/34865500/

Myocarditis following vaccination with Covid-19 in a large healthcare organization: pubmed.ncbi.nlm.nih.gov/34614329/

AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link: pubmed.ncbi.nlm.nih.gov/34560365/

COVID-19, Guillain-Barré and vaccineA dangerous mix: pubmed.ncbi.nlm.nih.gov/34108736/.

Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: pubmed.ncbi.nlm.nih.gov/34796417/.

Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine: link.springer.com/article/10.1007/s10072-021-05523-5.

COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy: onlinelibrary.wiley.com/doi/10.1002/ana.26258.

Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021: jamanetwork.com/journals/jama/fullarticle/2785009

A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34567447/

Guillain-Barré syndrome associated with COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34648420/.

Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine: jamanetwork.com/journals/jamaneurology/fullarticle/2783708

Guillain-Barre syndrome after COVID-19 vaccination in an adolescent: www.pedneur.com/article/S0887-8994(21)00221-6/fulltext.

Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination: pubmed.ncbi.nlm.nih.gov/34114256/.

Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34767184/.

Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients: pubmed.ncbi.nlm.nih.gov/34644738/.

Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: pubmed.ncbi.nlm.nih.gov/34649856/

A rare case of Guillain-Barré syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34671572/

Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33758714/

COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: pubmed.ncbi.nlm.nih.gov/34484780/

Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report; pubmed.ncbi.nlm.nih.gov/34779385/.

Miller Fisher syndrome after Pfizer COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34817727/.

Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination: pubmed.ncbi.nlm.nih.gov/34789193/.

Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34261746/

Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: pubmed.ncbi.nlm.nih.gov/34217513/.
0    k 17
function
#11 A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine (Pfizer): pubmed.ncbi.nlm.nih.gov/34871447/

Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: pubmed.ncbi.nlm.nih.gov/34579259/

A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN: pubmed.ncbi.nlm.nih.gov/34370408/.

A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S: pubmed.ncbi.nlm.nih.gov/34703690/.

Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: pubmed.ncbi.nlm.nih.gov/34810163/

Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: onlinelibrary.wiley.com/doi/10.1002/ana.26218.

Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: pubmed.ncbi.nlm.nih.gov/34482455/.

Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34114269/.

Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: pubmed.ncbi.nlm.nih.gov/34722067/

Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: pubmed.ncbi.nlm.nih.gov/33968610/

SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: pubmed.ncbi.nlm.nih.gov/34525410/

Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: pubmed.ncbi.nlm.nih.gov/34808658/

Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination: www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/ful.

Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence: pubmed.ncbi.nlm.nih.gov/34522557/

Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report: pubmed.ncbi.nlm.nih.gov/34763263/.

Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: pubmed.ncbi.nlm.nih.gov/34621891/

Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection: pubmed.ncbi.nlm.nih.gov/34697502/

Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy: pubmed.ncbi.nlm.nih.gov/33858693/

Acute transverse myelitis following inactivated COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34370410/

Acute transverse myelitis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34579245/.

A case of longitudinally extensive transverse myelitis following Covid-19 vaccination: pubmed.ncbi.nlm.nih.gov/34182207/

Post COVID-19 transverse myelitis; a case report with review of the literature: pubmed.ncbi.nlm.nih.gov/34457267/.

Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: pubmed.ncbi.nlm.nih.gov/34189662/

Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: pubmed.ncbi.nlm.nih.gov/34660149/

Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse myelitis in long-standing stable multiple sclerosis after vector-based vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/34131771/

A case series of acute pericarditis after vaccination with COVID-19 in the context of recent reports from Europe and the United States: pubmed.ncbi.nlm.nih.gov/34635376/

Acute pericarditis and cardiac tamponade after vaccination with Covid-19: pubmed.ncbi.nlm.nih.gov/34749492/

Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: pubmed.ncbi.nlm.nih.gov/34849667/

Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34319393/

Acute myopericarditis after COVID-19 vaccine in adolescents: pubmed.ncbi.nlm.nih.gov/34589238/

Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19: pubmed.ncbi.nlm.nih.gov/34149145/

Case report: symptomatic pericarditis post COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34693198/.

An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient: pubmed.ncbi.nlm.nih.gov/34797392/

Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): pubmed.ncbi.nlm.nih.gov/34862234/

Myocarditis after SARS-CoV-2 mRNA vaccination, a case series: pubmed.ncbi.nlm.nih.gov/34396358/.

Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient after Oxford-AstraZeneca SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34848426/.

Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: pubmed.ncbi.nlm.nih.gov/33946748/

Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: pubmed.ncbi.nlm.nih.gov/34591186/

Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34352309/

Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: pubmed.ncbi.nlm.nih.gov/34804803/.

Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2: pubmed.ncbi.nlm.nih.gov/34077572/

Retinal hemorrhage after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34884407/.

Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage can occur after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34859017/

Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report: pubmed.ncbi.nlm.nih.gov/34783899/

Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34549178/.

Brain death in a vaccinated patient with COVID-19 infection: pubmed.ncbi.nlm.nih.gov/34656887/

Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination: pubmed.ncbi.nlm.nih.gov/34236717/.

Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34729467/.

A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/33932458/

Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: pubmed.ncbi.nlm.nih.gov/34092400/742.

Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine: pubmed.ncbi.nlm.nih.gov/34754937/

Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: pubmed.ncbi.nlm.nih.gov/33771584/

Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination: pubmed.ncbi.nlm.nih.gov/34846583/

COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: pubmed.ncbi.nlm.nih.gov/34073536/

Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control study: pubmed.ncbi.nlm.nih.gov/34411532/

Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval: www.medrxiv.org/content/10.1101/2021.12.02.21267156v1

Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: pubmed.ncbi.nlm.nih.gov/33851711/

Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: pubmed.ncbi.nlm.nih.gov/34675550/.

Anaphylaxis after Modern COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/34734159/.

Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34698847/

Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: pubmed.ncbi.nlm.nih.gov/34020815/

Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020: pubmed.ncbi.nlm.nih.gov/33641264/

Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021: pubmed.ncbi.nlm.nih.gov/33641268/

Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: pubmed.ncbi.nlm.nih.gov/33834172/

Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: pubmed.ncbi.nlm.nih.gov/34579211/

Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result: pubmed.ncbi.nlm.nih.gov/34343674/

Acute myocardial infarction and myocarditis after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34586408/

Takotsubo syndrome after COVID-19 vaccination: pubmed.ncbi.nlm.nih.gov/34539938/.

Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: pubmed.ncbi.nlm.nih.gov/34731486/.

Premature myocardial infarction or side effect of COVID-19 vaccine: pubmed.ncbi.nlm.nih.gov/33824804/

Myocardial infarction, stroke, and pulmonary embolism...
0    k 15
suscripciones por RSS
ayuda
+mediatize
estadísticas
mediatize
mediatize